The company's principal activity is the development of drugs. The company is in the development stages and is conducting clinical evaluation and regulatory approval of neuroscience drugs. Its strategy is to in-license and develop early-stage and later-stage drug candidates that target major medical needs and can be commercialized. Currently, the company has two product candidates: memantime and xerecept (TM). Memantime is an orally dosed compound that helps in restoring the function of impaired neurons. Xerecept is applied for the treatment of brain swelling due to brain tumors. The company seeks partnerships with pharmaceutical and biotechnology companies to complete development and marketing of its product candidates. On 15-Jul-2004, the company acquired empire pharmaceuticals inc.
